In diseases where excessive CXCR4 signaling exacerbates pathology, such as certain inflammatory and metastatic cancers [17], targeting GPR15LG could attenuate CXCL12-driven responses. The gene discussed is CXCR4; the disease is metastatic malignant neoplasm.